Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epoetin alfa - Kirin-Amgen

Drug Profile

Epoetin alfa - Kirin-Amgen

Alternative Names: Epoetin - Amgen; Epoetin-α; Epogen; Epoimmun; Eprex; Erypo; Espo; Kirin EPO; KRN-5702; Li Xue Bao; Procrit; r-HuEPO; recombinant human EPO; recombinant human erythropoietin

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin-Amgen
  • Developer Janssen Biotech; Janssen-Cilag; Johnson & Johnson; Kyowa Hakko Kirin; Weihai Sinogen Pharmaceutical
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • No development reported Neurological disorders; Stroke

Most Recent Events

  • 05 Dec 2017 Efficacy and safery data from the phase III EPO-ANE-3010 trial in Anaemia presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
  • 24 Mar 2017 Agence Nationale de Sécurité du Médicament et des Produits de Santé approves epoetin alfa for symptomatic Anaemia in adult patients with primary myelodysplastic syndromes in France
  • 13 Jun 2016 Efficacy and adverse events data from a phase III trial in Anaemia presented at the 21st Annual Congress of the European Hematology Association (EHA-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top